Recent Finacing
Recent Raise
BioShin is Biohaven’s Asia‑Pacific biopharmaceutical subsidiary based in Shanghai that holds regional rights (ex‑Japan) and conducts clinical development of rimegepant and troriluzole across APAC.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at BioShin.
